Influencing factors of end-of-dose failure in patients with cancer pain after oral oxycodone sustained-release tablets: a retrospective, case–control study
| Autor: | Hang-Xing Huang, Yamin Huang, Lu Zhang, Ke-Ke Liu, Jian Xiao, Wen-Hui Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Administration Oral 03 medical and health sciences 0302 clinical medicine 030202 anesthesiology Rating scale Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Head and neck Retrospective Studies business.industry Case-control study Cancer Pain General Medicine Odds ratio Middle Aged medicine.disease medicine.anatomical_structure Oncology Nasopharyngeal carcinoma Case-Control Studies Delayed-Action Preparations 030220 oncology & carcinogenesis Abdomen Female Cancer pain business Oxycodone Tablets medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 51:932-941 |
| ISSN: | 1465-3621 |
| Popis: | Objective Comparing the characteristics of end-of-dose failure patients and non-end-of-dose failure patients in the Chinese population and exploring the factors that may affect the occurrence of end-of-dose failure in cancer pain patients. Methods The outpatient with cancer pain from 2016 to 2019 were collected through hospital information system, and patients were included who met the following criteria: patients with the average numerical rating scale ≥4 points within 3 days after taking the oxycodone sustained-release preparation, titrated to an effective therapeutic dose suitable for patients, had at least two clinical visits information of the patient with a minimum of ≥3 days between visits, the average numerical rating scale of the next visit after the treatment of occasional pain is ≥4, and were divided into end-of-dose failure group and non-end-of-dose failure group. Results Age (P Conclusions Younger patients are more likely to develop end-of-dose failure. Patients diagnosed with nasopharyngeal cancer, with pain in the head and neck and abdomen, and with liver metastases have a lower incidence of end-of-dose failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|